Propath partners with NanoString to bring the GeoMx Cancer Transcriptome Atlas to Europe

Propath announces that it now offers a turn-key service to run the NanoString GeoMx Cancer Transcriptome Atlas assay for spatial profiling of 1,800 genes on single clinical or experimental samples.

Designed for comprehensive profiling of tumour biology, the tumour microenvironment, and the immune response, the panel profiles RNA expression of over 1,800 genes simultaneously with spatial resolution in any region of interest from a single tissue section.

The assay is compatible with the most challenging sample types, including FFPE, fresh frozen tissue and TMAs; and preserves tissues so that they can be reused.

Propath offers a comprehensive service, from sample preparation to data analysis, with reporting from as little as four weeks from sample receipt. Choose from one of NanoString validated protein or mRNA panels, with the option to spike-in additional targets. Alternatively, Propath can assist clients in designing their own custom panel.

Outsourced R&D - Done better.

At Propath we approach biopharma R&D differently. Say goodbye to Large CRO frustrations –and hello to a more responsive, agile and efficient level of service.